Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Haematological Malignancy
Acute Myeloid Leukemia
Non Hodgkin Lymphoma
Multiple Myeloma
Higher-risk Myelodysplastic Syndrome
Peripheral T Cell Lymphoma

Interventions

DRUG: CCS1477
DRUG: Pomalidomide
DRUG: Dexamethasone
DRUG: Azacitidine
DRUG: Venetoclax
DRUG: Bortezomib
DRUG: Ixazomib
DRUG: Elranatamab
DRUG: Teclistamab
DRUG: Lenalidomide
DRUG: Daratumumab

Sponsor

CellCentric Ltd.